Industry Research Reports
Home > Reports > Service & Software > Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Industry: Service & Software
Published Date: 2024-10-11
Pages: 99 Pages
Report ld: 3341547
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oligonucleotide Drug CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oligonucleotide Drug CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Oligonucleotide Drug CDMO Services in SME Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Oligonucleotide Drug CDMO Services include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Drug CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Drug CDMO Services.
The Oligonucleotide Drug CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide Drug CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Drug CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
MARKET SEGMENTATION
By Company
- Bachem
- WuXi TIDES
- Ajinomoto Co
- Waters
- AGC Biologics
- Merck KGaA
- EUROAPI
- CordenPharma
- Cytiva
- TriLink BioTechnologies
- Medicilon
- General Biol
- BioSpring
- Bio-Synthesis Inc
- Aurisco
- Suzhou Olipharma Co.,Ltd
- Porton
- RIBOPharm
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- API
- Preparation
Segment by Application
- SME Pharmaceutical Company
- Large Pharmaceutical Company
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Drug CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 API
1.2.3 Preparation
1.3 Market by Application
1.3.1 Global Oligonucleotide Drug CDMO Services Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Drug CDMO Services Market Perspective (2019-2030)
2.2 Global Oligonucleotide Drug CDMO Services Growth Trends by Region
2.2.1 Global Oligonucleotide Drug CDMO Services Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oligonucleotide Drug CDMO Services Historic Market Size by Region (2019-2024)
2.2.3 Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (2025-2030)
2.3 Oligonucleotide Drug CDMO Services Market Dynamics
2.3.1 Oligonucleotide Drug CDMO Services Industry Trends
2.3.2 Oligonucleotide Drug CDMO Services Market Drivers
2.3.3 Oligonucleotide Drug CDMO Services Market Challenges
2.3.4 Oligonucleotide Drug CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue
3.1.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Players (2019-2024)
3.2 Global Oligonucleotide Drug CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide Drug CDMO Services Revenue
3.4 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio
3.4.1 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Drug CDMO Services Revenue in 2023
3.5 Global Key Players of Oligonucleotide Drug CDMO Services Head office and Area Served
3.6 Global Key Players of Oligonucleotide Drug CDMO Services, Product and Application
3.7 Global Key Players of Oligonucleotide Drug CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Drug CDMO Services Breakdown Data by Type
4.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Type (2019-2024)
4.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2025-2030)
5 Oligonucleotide Drug CDMO Services Breakdown Data by Application
5.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Application (2019-2024)
5.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oligonucleotide Drug CDMO Services Market Size (2019-2030)
6.2 North America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024)
6.4 North America Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Drug CDMO Services Market Size (2019-2030)
7.2 Europe Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024)
7.4 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size (2019-2030)
8.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2019-2024)
8.4 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide Drug CDMO Services Market Size (2019-2030)
9.2 Latin America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024)
9.4 Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size (2019-2030)
10.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024)
10.4 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Oligonucleotide Drug CDMO Services Introduction
11.1.4 Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.1.5 Bachem Recent Development
11.2 WuXi TIDES
11.2.1 WuXi TIDES Company Details
11.2.2 WuXi TIDES Business Overview
11.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Introduction
11.2.4 WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.2.5 WuXi TIDES Recent Development
11.3 Ajinomoto Co
11.3.1 Ajinomoto Co Company Details
11.3.2 Ajinomoto Co Business Overview
11.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Introduction
11.3.4 Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.3.5 Ajinomoto Co Recent Development
11.4 Waters
11.4.1 Waters Company Details
11.4.2 Waters Business Overview
11.4.3 Waters Oligonucleotide Drug CDMO Services Introduction
11.4.4 Waters Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.4.5 Waters Recent Development
11.5 AGC Biologics
11.5.1 AGC Biologics Company Details
11.5.2 AGC Biologics Business Overview
11.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Introduction
11.5.4 AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.5.5 AGC Biologics Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Introduction
11.6.4 Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.6.5 Merck KGaA Recent Development
11.7 EUROAPI
11.7.1 EUROAPI Company Details
11.7.2 EUROAPI Business Overview
11.7.3 EUROAPI Oligonucleotide Drug CDMO Services Introduction
11.7.4 EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.7.5 EUROAPI Recent Development
11.8 CordenPharma
11.8.1 CordenPharma Company Details
11.8.2 CordenPharma Business Overview
11.8.3 CordenPharma Oligonucleotide Drug CDMO Services Introduction
11.8.4 CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.8.5 CordenPharma Recent Development
11.9 Cytiva
11.9.1 Cytiva Company Details
11.9.2 Cytiva Business Overview
11.9.3 Cytiva Oligonucleotide Drug CDMO Services Introduction
11.9.4 Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.9.5 Cytiva Recent Development
11.10 TriLink BioTechnologies
11.10.1 TriLink BioTechnologies Company Details
11.10.2 TriLink BioTechnologies Business Overview
11.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Introduction
11.10.4 TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.10.5 TriLink BioTechnologies Recent Development
11.11 Medicilon
11.11.1 Medicilon Company Details
11.11.2 Medicilon Business Overview
11.11.3 Medicilon Oligonucleotide Drug CDMO Services Introduction
11.11.4 Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.11.5 Medicilon Recent Development
11.12 General Biol
11.12.1 General Biol Company Details
11.12.2 General Biol Business Overview
11.12.3 General Biol Oligonucleotide Drug CDMO Services Introduction
11.12.4 General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.12.5 General Biol Recent Development
11.13 BioSpring
11.13.1 BioSpring Company Details
11.13.2 BioSpring Business Overview
11.13.3 BioSpring Oligonucleotide Drug CDMO Services Introduction
11.13.4 BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.13.5 BioSpring Recent Development
11.14 Bio-Synthesis Inc
11.14.1 Bio-Synthesis Inc Company Details
11.14.2 Bio-Synthesis Inc Business Overview
11.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Introduction
11.14.4 Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.14.5 Bio-Synthesis Inc Recent Development
11.15 Aurisco
11.15.1 Aurisco Company Details
11.15.2 Aurisco Business Overview
11.15.3 Aurisco Oligonucleotide Drug CDMO Services Introduction
11.15.4 Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.15.5 Aurisco Recent Development
11.16 Suzhou Olipharma Co.,Ltd
11.16.1 Suzhou Olipharma Co.,Ltd Company Details
11.16.2 Suzhou Olipharma Co.,Ltd Business Overview
11.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Introduction
11.16.4 Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.16.5 Suzhou Olipharma Co.,Ltd Recent Development
11.17 Porton
11.17.1 Porton Company Details
11.17.2 Porton Business Overview
11.17.3 Porton Oligonucleotide Drug CDMO Services Introduction
11.17.4 Porton Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.17.5 Porton Recent Development
11.18 RIBOPharm
11.18.1 RIBOPharm Company Details
11.18.2 RIBOPharm Business Overview
11.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Introduction
11.18.4 RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024)
11.18.5 RIBOPharm Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of API
Table 3. Key Players of Preparation
Table 4. Global Oligonucleotide Drug CDMO Services Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Oligonucleotide Drug CDMO Services Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Oligonucleotide Drug CDMO Services Market Share by Region (2019-2024)
Table 8. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Oligonucleotide Drug CDMO Services Market Share by Region (2025-2030)
Table 10. Oligonucleotide Drug CDMO Services Market Trends
Table 11. Oligonucleotide Drug CDMO Services Market Drivers
Table 12. Oligonucleotide Drug CDMO Services Market Challenges
Table 13. Oligonucleotide Drug CDMO Services Market Restraints
Table 14. Global Oligonucleotide Drug CDMO Services Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Oligonucleotide Drug CDMO Services Market Share by Players (2019-2024)
Table 16. Global Top Oligonucleotide Drug CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drug CDMO Services as of 2023)
Table 17. Ranking of Global Top Oligonucleotide Drug CDMO Services Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Oligonucleotide Drug CDMO Services Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Oligonucleotide Drug CDMO Services, Headquarters and Area Served
Table 20. Global Key Players of Oligonucleotide Drug CDMO Services, Product and Application
Table 21. Global Key Players of Oligonucleotide Drug CDMO Services, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Oligonucleotide Drug CDMO Services Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2019-2024)
Table 25. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2025-2030)
Table 27. Global Oligonucleotide Drug CDMO Services Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2019-2024)
Table 29. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2025-2030)
Table 31. North America Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2025-2030) & (US$ Million)
Table 46. Bachem Company Details
Table 47. Bachem Business Overview
Table 48. Bachem Oligonucleotide Drug CDMO Services Product
Table 49. Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 50. Bachem Recent Development
Table 51. WuXi TIDES Company Details
Table 52. WuXi TIDES Business Overview
Table 53. WuXi TIDES Oligonucleotide Drug CDMO Services Product
Table 54. WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 55. WuXi TIDES Recent Development
Table 56. Ajinomoto Co Company Details
Table 57. Ajinomoto Co Business Overview
Table 58. Ajinomoto Co Oligonucleotide Drug CDMO Services Product
Table 59. Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 60. Ajinomoto Co Recent Development
Table 61. Waters Company Details
Table 62. Waters Business Overview
Table 63. Waters Oligonucleotide Drug CDMO Services Product
Table 64. Waters Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 65. Waters Recent Development
Table 66. AGC Biologics Company Details
Table 67. AGC Biologics Business Overview
Table 68. AGC Biologics Oligonucleotide Drug CDMO Services Product
Table 69. AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 70. AGC Biologics Recent Development
Table 71. Merck KGaA Company Details
Table 72. Merck KGaA Business Overview
Table 73. Merck KGaA Oligonucleotide Drug CDMO Services Product
Table 74. Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 75. Merck KGaA Recent Development
Table 76. EUROAPI Company Details
Table 77. EUROAPI Business Overview
Table 78. EUROAPI Oligonucleotide Drug CDMO Services Product
Table 79. EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 80. EUROAPI Recent Development
Table 81. CordenPharma Company Details
Table 82. CordenPharma Business Overview
Table 83. CordenPharma Oligonucleotide Drug CDMO Services Product
Table 84. CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 85. CordenPharma Recent Development
Table 86. Cytiva Company Details
Table 87. Cytiva Business Overview
Table 88. Cytiva Oligonucleotide Drug CDMO Services Product
Table 89. Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 90. Cytiva Recent Development
Table 91. TriLink BioTechnologies Company Details
Table 92. TriLink BioTechnologies Business Overview
Table 93. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product
Table 94. TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 95. TriLink BioTechnologies Recent Development
Table 96. Medicilon Company Details
Table 97. Medicilon Business Overview
Table 98. Medicilon Oligonucleotide Drug CDMO Services Product
Table 99. Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 100. Medicilon Recent Development
Table 101. General Biol Company Details
Table 102. General Biol Business Overview
Table 103. General Biol Oligonucleotide Drug CDMO Services Product
Table 104. General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 105. General Biol Recent Development
Table 106. BioSpring Company Details
Table 107. BioSpring Business Overview
Table 108. BioSpring Oligonucleotide Drug CDMO Services Product
Table 109. BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 110. BioSpring Recent Development
Table 111. Bio-Synthesis Inc Company Details
Table 112. Bio-Synthesis Inc Business Overview
Table 113. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product
Table 114. Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 115. Bio-Synthesis Inc Recent Development
Table 116. Aurisco Company Details
Table 117. Aurisco Business Overview
Table 118. Aurisco Oligonucleotide Drug CDMO Services Product
Table 119. Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 120. Aurisco Recent Development
Table 121. Suzhou Olipharma Co.,Ltd Company Details
Table 122. Suzhou Olipharma Co.,Ltd Business Overview
Table 123. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product
Table 124. Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 125. Suzhou Olipharma Co.,Ltd Recent Development
Table 126. Porton Company Details
Table 127. Porton Business Overview
Table 128. Porton Oligonucleotide Drug CDMO Services Product
Table 129. Porton Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 130. Porton Recent Development
Table 131. RIBOPharm Company Details
Table 132. RIBOPharm Business Overview
Table 133. RIBOPharm Oligonucleotide Drug CDMO Services Product
Table 134. RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2019-2024) & (US$ Million)
Table 135. RIBOPharm Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
Table 139. Authors List of This Report
List of Figures
Figure 1. Oligonucleotide Drug CDMO Services Picture
Figure 2. Global Oligonucleotide Drug CDMO Services Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oligonucleotide Drug CDMO Services Market Share by Type: 2023 VS 2030
Figure 4. API Features
Figure 5. Preparation Features
Figure 6. Global Oligonucleotide Drug CDMO Services Market Size by Application (2024-2030) & (US$ Million)
Figure 7. Global Oligonucleotide Drug CDMO Services Market Share by Application: 2023 VS 2030
Figure 8. SME Pharmaceutical Company Case Studies
Figure 9. Large Pharmaceutical Company Case Studies
Figure 10. Oligonucleotide Drug CDMO Services Report Years Considered
Figure 11. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Oligonucleotide Drug CDMO Services Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Oligonucleotide Drug CDMO Services Market Share by Region: 2023 VS 2030
Figure 14. Global Oligonucleotide Drug CDMO Services Market Share by Players in 2023
Figure 15. Global Top Oligonucleotide Drug CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drug CDMO Services as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Oligonucleotide Drug CDMO Services Revenue in 2023
Figure 17. North America Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Oligonucleotide Drug CDMO Services Market Share by Country (2019-2030)
Figure 19. United States Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Oligonucleotide Drug CDMO Services Market Share by Country (2019-2030)
Figure 23. Germany Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Region (2019-2030)
Figure 31. China Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Oligonucleotide Drug CDMO Services Market Share by Country (2019-2030)
Figure 39. Mexico Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Country (2019-2030)
Figure 43. Turkey Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. UAE Oligonucleotide Drug CDMO Services Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Bachem Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 47. WuXi TIDES Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 48. Ajinomoto Co Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 49. Waters Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 50. AGC Biologics Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 51. Merck KGaA Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 52. EUROAPI Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 53. CordenPharma Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 54. Cytiva Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 55. TriLink BioTechnologies Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 56. Medicilon Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 57. General Biol Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 58. BioSpring Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 59. Bio-Synthesis Inc Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 60. Aurisco Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 61. Suzhou Olipharma Co.,Ltd Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 62. Porton Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 63. RIBOPharm Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2019-2024)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Oligonucleotide Drug CDMO Services market?
The top companies in the global Oligonucleotide Drug CDMO Services market are Bachem、WuXi TIDES、Ajinomoto Co.
Related Reports
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 146
USD 4900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 107
USD 4250.00
(Single User License)
Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-08
Pages: 135
USD 3950.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2026
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-08
Pages: 122
USD 2900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 106
USD 4250.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 158
USD 4900.00
(Single User License)
Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-12
Pages: 138
USD 3950.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2025
The global market for Oligonucleotide Drug CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-12
Pages: 99
USD 2900.00
(Single User License)
Global and United States Oligonucleotide Drug CDMO Services Market Report & Forecast 2024-2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 127
USD 4350.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Insights, Forecast to 2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 152
USD 4900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 146
USD 4900.00 (Single User License)Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 107
USD 4250.00 (Single User License)Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-08
Pages: 135
USD 3950.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Research Report 2026
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-08
Pages: 122
USD 2900.00 (Single User License)Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 106
USD 4250.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 158
USD 4900.00 (Single User License)Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-12
Pages: 138
USD 3950.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Research Report 2025
The global market for Oligonucleotide Drug CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-12
Pages: 99
USD 2900.00 (Single User License)Global and United States Oligonucleotide Drug CDMO Services Market Report & Forecast 2024-2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 127
USD 4350.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Insights, Forecast to 2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 152
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now